Phase 1 Study of Second Group Psilocybin Therapy for Partial Responders

A single-arm Phase 1 study assessed the safety and preliminary efficacy of a second group retreat psilocybin therapy experience for 13 partial responders with metastatic cancer. The protocol included a higher initial dose, an optional booster, and no antidepressant tapering requirement. Results include safety data, Hospital Anxiety and Depression Scale (HADS) scores, and Mystical Experience Questionnaire (MEQ) outcomes collected up to 24-week follow-up.

Use Cases

• Analyzing safety profiles based on reported adverse events like hypertension and nausea.
• Modeling treatment efficacy based on changes in Hospital Anxiety and Depression Scale (HADS) scores.
• Studying mystical experience outcomes based on Mystical Experience Questionnaire (MEQ) scores.
• Investigating group therapy dynamics based on social support and cohesion measures.

Strengths

• Includes detailed clinical results for 13 participants with mean age and gender breakdown.
• Reports specific outcome measures: HADS scores decreased from 15.08 to 9.00 at Day +8.
• Provides longitudinal data with follow-up assessments maintained through 24 weeks.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data is presented in a PDF report, requiring extraction for computational analysis.

Provenance

Source

Anthony L. Back via figshare.

Collection Method

Single-arm Phase 1 clinical study.

Time Range

Study period not specified; data includes 24-week follow-up.

Freshness

Last updated 2026-04-14 13:58:06; freshness should be verified.

Geography

Geographic coverage of participants is not specified.